{"protocolSection": {"identificationModule": {"nctId": "NCT01365481", "orgStudyIdInfo": {"id": "CVAL489K2305"}, "secondaryIdInfos": [{"id": "2009-017594-37", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age", "officialTitle": "A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease"}, "statusModule": {"statusVerifiedDate": "2016-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-05-09", "studyFirstSubmitQcDate": "2011-06-01", "studyFirstPostDateStruct": {"date": "2011-06-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-09", "resultsFirstSubmitQcDate": "2016-04-19", "resultsFirstPostDateStruct": {"date": "2016-04-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-06-13", "lastUpdatePostDateStruct": {"date": "2016-07-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease."}, "conditionsModule": {"conditions": ["Hypertension", "Chronic Kidney Disease"], "keywords": ["Hypertension, pediatric", "Hypertension with or without chronic kidney disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 150, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "valsartan", "type": "EXPERIMENTAL", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.", "interventionNames": ["Drug: Valsartan", "Drug: amlodipine", "Drug: Hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily", "armGroupLabels": ["valsartan"], "otherNames": ["VAL489"]}, {"type": "DRUG", "name": "amlodipine", "description": "added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose", "armGroupLabels": ["valsartan"]}, {"type": "DRUG", "name": "Hydrochlorothiazide", "description": "added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose", "armGroupLabels": ["valsartan"], "otherNames": ["HCTZ"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)"}], "secondaryOutcomes": [{"measure": "Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height", "description": "Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height", "timeFrame": "End Point (Week 78 or Last observation carried forward (LOCF)"}, {"measure": "Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point", "description": "Percentage of Patients with CKD who had Urine albumin creatinine reduction \\>/= 50% from baseline", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)"}, {"measure": "Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point", "description": "Percentage of Patients with CKD who had eGFR decrease \\> 25 % from Baseline", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Documented diagnosis of hypertension\n* able to swallow a tablet\n* body weight \u226518 kg and \u2264160 kg at baseline\n* MSSBP must be \u2265 95th percentile and \u226425% above the 95th percentile for age, gender and height.\n\nExclusion Criteria:\n\n* Any clinically significant physical abnormalities or clinically relevant abnormal laboratory values (other than those relating to renal function) obtained at the screening visit. Including the following:\n\n  1. AST/SGOT or ALT/SGPT \\>3 times the upper limit of the reference range. Patients known to have active or chronic hepatitis were excluded.\n  2. Total bilirubin \\>2 times the upper limit of the reference range\n  3. Estimated GFR \\<30 mL/min/1.73m\u00b2 (calculated using Modified Schwartz Formula)\n  4. WBC count \\<3000/mm\u00b3\n  5. Platelet count \\<100,000/mm\u00b3\n  6. Serum potassium \\>5.3 mmol/L\n  7. Hemoglobin \\<8 g/dL\n* Uncontrolled diabetes mellitus\n* Unilateral, bilateral and graft renal artery stenosis\n* Current diagnosis of heart failure (New York Heart Association Class II-IV)\n* Patients taking any of the following concomitant medications following screening: Renin-angiotensin receptor(RAAS) blockers other than study drug, Lithium, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels, Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors, acetylsalicylic acid \\>3g/day, and non-selective NSAIDs, Antidepressant drugs in the class of Monoamine oxidase (MAO) inhibitors (e.g. phenelzine), Chronic use of stimulant therapy for Attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) -Patients who demonstrate clinically significant ECG abnormalities such as concurrent potentially life threatening arrhythmia or symptomatic arrhythmia and patients with second or third degree heart block without a pacemaker.\n* Coarctation of the aorta with a gradient of \\>=30 mmHg\n* Previous solid organ transplantation except renal transplantation.\n* Patients known to be positive for the human immunodeficiency virus (HIV)\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug\n* Known or suspected contraindications to the study drug, including severe hepatic impairment, biliary cirrhosis, cholestasis and history of allergy to ARBs and/or angiotensin-converting enzymes (ACE) and/or Direct Renin Inhibitors (DRIs)\n* History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.\n* History or evidence of drug or alcohol abuse within the last 12 months.\n* Female patients of child-bearing potential, defined as all female patients physiologically capable of becoming pregnant, unless they are willing to use highly effective contraception during the study\n* Pregnant or nursing (lactating) female patients\n* Participation in any investigational drug study within 30 days prior to screening or within 5 elimination half-lives of the study drug prior to screening, or whichever is longer.\n* History of hypersensitivity to the study drug or to drugs of similar chemical classes.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Bucaramanga", "state": "Santander", "zip": "0001", "country": "Colombia", "geoPoint": {"lat": 7.12539, "lon": -73.1198}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Cali", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Novartis Investigative Site", "city": "Helsinki", "zip": "00029", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Novartis Investigative Site", "city": "Bochum", "zip": "44791", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Novartis Investigative Site", "city": "Cottbus", "zip": "03048", "country": "Germany", "geoPoint": {"lat": 51.75769, "lon": 14.32888}}, {"facility": "Novartis Investigative Site", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Novartis Investigative Site", "city": "Homburg", "zip": "66421", "country": "Germany", "geoPoint": {"lat": 49.32637, "lon": 7.33867}}, {"facility": "Novartis Investigative Site", "city": "Rostock", "zip": "18107", "country": "Germany", "geoPoint": {"lat": 54.0887, "lon": 12.14049}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01010", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1101", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Warszawa", "zip": "04-154", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novartis Investigative Site", "city": "Cluj-Napoca", "state": "Jud Cluj", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Tg. Mures", "state": "jud Mures", "zip": "540104", "country": "Romania"}, {"facility": "Novartis Investigative Site", "city": "Timisoara", "state": "jud. Timis", "zip": "300011", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "041451", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "20395", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Iasi", "zip": "700309", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Novartis Investigative Site", "city": "Kazan", "zip": "420012", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "119991", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "125315", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "127412", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Voronezh", "zip": "394036", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "119074", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "229899", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "These 2 groups were not randomized and considered to be 2 different populations since the patients in the valsartan+antihypertensive group had concomitant antihypertensive usage per individual patient's conditions at any time during treatment period.", "recruitmentDetails": "A 1 arm study of valsartan but with 2 groups for analyses. The valsartan +antihypertensive group includes the patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.", "groups": [{"id": "FG000", "title": "CKD Patients: Valsartan + Antihypertensive Group", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "FG001", "title": "CKD Patients: Valsartan Alone", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}, {"id": "FG002", "title": "Non-CKD Patients: Valsartan + Antihypertensive Group", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "FG003", "title": "Non-CKD Patients: Valsartan Alone", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "52"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "57"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "37"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "CKD Patients: Valsartan + Antihypertensive Group", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "BG001", "title": "CKD Patients: Valsartan Alone", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}, {"id": "BG002", "title": "Non-CKD Patients: Valsartan + Antihypertensive Group", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "BG003", "title": "Non-CKD Patients: Valsartan Alone", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "57"}, {"groupId": "BG004", "value": "150"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.90", "spread": "3.35"}, {"groupId": "BG001", "value": "12.30", "spread": "3.20"}, {"groupId": "BG002", "value": "13.79", "spread": "2.64"}, {"groupId": "BG003", "value": "14.37", "spread": "2.83"}, {"groupId": "BG004", "value": "13.36", "spread": "3.130"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "6 - 11 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "10"}, {"groupId": "BG004", "value": "45"}]}]}, {"title": "12 - 17 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "47"}, {"groupId": "BG004", "value": "105"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "20"}, {"groupId": "BG004", "value": "51"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "37"}, {"groupId": "BG004", "value": "99"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.", "populationDescription": "The Full Analysis set (FAS) included all patients who entered the treatment period. ) This OM looked at the Valsartan + Antihypertensive and Valsartan alone for ALL patients and did not break up the analysis between CKD and non-CKD patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeter(s) of mercury (mmHg)", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)", "groups": [{"id": "OG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "OG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.3", "spread": "13.69"}, {"groupId": "OG001", "value": "-15.5", "spread": "13.35"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height", "description": "Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height", "populationDescription": "The Full Analysis set (FAS) included all patients who entered the treatment period. This analysis includes only participants with baseline MSSBP or MSDBP or (MSSBP or MSDBP combined) \u226595th percentile for gender, age and height. n analyzed is displayed in left column. This OM did not break up the analysis between CKD and non-CKD patients.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Participants", "timeFrame": "End Point (Week 78 or Last observation carried forward (LOCF)", "groups": [{"id": "OG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "OG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"title": "MSSBP (n=39, 105)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "90"}]}]}, {"title": "MSDBP (n=28, 51)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "47"}]}]}, {"title": "MSSBP and MSDBP combined (n=40, 105)", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "88"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point", "description": "Percentage of Patients with CKD who had Urine albumin creatinine reduction \\>/= 50% from baseline", "populationDescription": "The Safety set (SAF) included all patients who received at least one dose of study medication that has Chronic Kidney Disease (CKD) only", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)", "groups": [{"id": "OG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "OG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.0", "spread": "404.08"}, {"groupId": "OG001", "value": "41.9", "spread": "138.66"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.", "populationDescription": "The Full Analysis set (FAS) included all patients who entered the treatment period. ) This OM looked at the Valsartan + Antihypertensive and Valsartan alone for ALL patients and did not break up the analysis between CKD and non-CKD patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeter(s) of mercury (mmHg)", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)", "groups": [{"id": "OG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "OG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.3", "spread": "11.94"}, {"groupId": "OG001", "value": "-10.8", "spread": "11.45"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point", "description": "Percentage of Patients with CKD who had eGFR decrease \\> 25 % from Baseline", "populationDescription": "The Safety set (SAF) included all patients who received at least one dose of study medication.that has Chronic Kidney Disease (CKD)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline, End Point (Week 78 or Last observation carried forward (LOCF)", "groups": [{"id": "OG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study."}, {"id": "OG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.4", "spread": "404.08"}, {"groupId": "OG001", "value": "27.5", "spread": "138.66"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan + Antihypertensive Group", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.", "seriousNumAffected": 8, "seriousNumAtRisk": 41, "otherNumAffected": 34, "otherNumAtRisk": 41}, {"id": "EG001", "title": "Valsartan Alone", "description": "Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg.", "seriousNumAffected": 7, "seriousNumAtRisk": 109, "otherNumAffected": 68, "otherNumAtRisk": 109}, {"id": "EG002", "title": "CKD Patients: Valsartan + Antihypertensive Group", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.", "seriousNumAffected": 7, "seriousNumAtRisk": 23, "otherNumAffected": 18, "otherNumAtRisk": 23}, {"id": "EG003", "title": "CKD Patients: Valsartan Alone", "description": "CKD Patients - Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg.", "seriousNumAffected": 4, "seriousNumAtRisk": 52, "otherNumAffected": 36, "otherNumAtRisk": 52}, {"id": "EG004", "title": "Non-CKD Patients: Valsartan + Antihypertensive Group", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 18, "otherNumAffected": 16, "otherNumAtRisk": 18}, {"id": "EG005", "title": "Non-CKD Patients: Valsartan Alone", "description": "Non-CKD patients-Valsartan starting dose: \u226518 kg to \\<35 kg is 40 mg, \u226535 kg to \\<80 kg is 80 mg, \u226580 kg to \u2264160 kg is 160 mg for 1 week then Valsartan maintenance dose: \u226518 kg to \\<35 kg is 80 mg, \u226535 kg to \\<80 kg is 160 mg, \u226580 kg to \u2264160 kg is 320 mg.", "seriousNumAffected": 3, "seriousNumAtRisk": 57, "otherNumAffected": 32, "otherNumAtRisk": 57}], "seriousEvents": [{"term": "Febrile neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Oesophageal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Face oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Glomerular filtration rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Synovitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Drug abuse", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "IgA nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Lupus nephritis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Nephrotic syndrome", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Neurogenic bladder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}], "otherEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Myopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Retinal vascular disorder", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 57}]}, {"term": "Acarodermatitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Enterobiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Mycoplasma infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 8, "numAtRisk": 57}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 57}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 57}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Hyperphosphataemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 11, "numAtRisk": 57}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 12, "numAtRisk": 57}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Micturition urgency", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 57}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Papule", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Pallor", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 52}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 57}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 -778 -8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Argentina", "India"]}, "conditionBrowseModule": {"meshes": [{"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000051436", "term": "Renal Insufficiency, Chronic"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}, {"id": "D000051437", "term": "Renal Insufficiency"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10698", "name": "Kidney Diseases", "asFound": "Kidney Disease", "relevance": "HIGH"}, {"id": "M26718", "name": "Renal Insufficiency", "relevance": "LOW"}, {"id": "M26717", "name": "Renal Insufficiency, Chronic", "asFound": "Chronic Kidney Disease", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}